Machine learning-assisted prediction of 5-year mortality in chronic kidney disease: the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD).
Aug 2026· Kidney Research and Clinical Practice· 0 citations· 46 references
Medicine
TL;DR
The CatBoost-based ML model accurately predicts 5-year mortality in non-dialysis CKD patients using five readily available clinical parameters and it is expected that the clinical implementation of this model may offer a practical method for early risk stratification and personalized management.
Abstract
Background
Mortality prediction models for patients with non-dialysis chronic kidney disease (CKD) remain limited despite their clinical importance. While machine learning (ML) offers the potential to improve prediction accuracy, its "black-box" nature has hindered clinical adoption. This study aimed to develop and validate an interpretable ML model for predicting 5-year all-cause mortality in patients with non-dialysis CKD and to deploy it as a user-friendly web-based risk stratification tool.
Methods
We analyzed 1,858 patients (94 deaths) from a prospective cohort of non-dialysis CKD patients. Several ML algorithms including CatBoost were trained and compared with conventional logistic regression. SHapley Additive exPlanations (SHAP) analysis was employed to identify key prognostic features and ensure model interpretability. The final simplified model was externally validated in an independent cohort of 348 CKD patients.
Results
The CatBoost model demonstrated superior performance (area under the curve [AUC], 0.813; 95% confidence interval [CI], 0.737-0.888; p = 0.04) compared to logistic regression (AUC, 0.747; 95% CI, 0.655-0.840). A simplified model using only the top-5 SHAP-ranked features-age, estimated glomerular filtration rate, serum albumin, spot urine protein-to-creatinine ratio, and serum total calcium-maintained robust predictive accuracy in the external validation cohort (AUC, 0.795). Notably, SHAP visualization revealed a U-shaped relationship for serum calcium, identifying hypocalcemia as a significant and under-recognized mortality risk factor.
Conclusion
The CatBoost-based ML model accurately predicts 5-year mortality in non-dialysis CKD patients using five readily available clinical parameters. We expect that the clinical implementation of this model may offer a practical method for early risk stratification and personalized management.
BACKGROUND
Cardiovascular disease (CVD) drives mortality in chronic kidney disease (CKD) patients. Conventional risk tools underperform in CKD, and few machine learning (ML) models undergo cross-national validation. We developed interpretable ML models for classifying CVD amongst Chinese and US middle-aged and elderly...
Yan Zhang, Kai-Hang Xu, Hao-Yao Zhang et al.· Diabetes, obesity and metabo...· 0 citations
A CatBoost-based machine learning model incorporating 32 clinically accessible variables showed good predictive performance for in-hospital mortality in patients with diabetes and SA-AKI, supporting early risk stratification and clinical decision-making.
Yan-Ni Wang, Hongjie Shen, Sheng-Ze Wu et al.· Journal of Intensive Care Me...· 0 citations
Logistic Regression showed potential as an interpretable early ICU risk-stratification tool and externally validated machine learning models for in-hospital mortality prediction in patients with diabetes and ARDS.
Ya-Lin Dong, Meng-Xue Hou, Qian-Qian Wang et al.· Shock· 0 citations
The XGB model incorporating LAD, BUN, RATD, RDW, RVD and PE exhibits excellent and robust predictive performance in both internal and temporal external validation cohorts, and significantly outperforms conventional echocardiography.
Meng-Xing Chen, Yang Zhang, Li Fan et al.· BMC Nephrology· 0 citations
An interpretable Random Forest model employing eight routinely available indicators accurately predicts AKI in septic MM patients, bridging algorithmic complexity and bedside applicability, and may facilitate early risk stratification and personalized renal protection in this high-risk group.
The results show how a combination of explainable ML and accessible clinical biomarkers can offer a precise, transparent, and clinically interpretable framework for early CKD diagnosis, risk stratification, and informed clinical decision making.
M. Khuntia, Hariballav Mahapatra, N. Lodha· Kidneys· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.